Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya. E-mail:

Slides:



Advertisements
Similar presentations
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Advertisements

Bioequivalence Studies Anoop Agarwal
III. Drug Metabolism  The aim of drug metabolism is to convert lipid soluble (non polar) drugs to polar metabolites easily excreted in urine.  The liver.
Introduction to Pharmacology. Overview Pharmaceutics Pharmacokinetics Pharmacodynamics.
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Introduction to the Discussion of Bioequivalence.
6/10/20151Prof. Mazen Qato. Objectives At the end of this sessions students should be able to: 1. List and discuss common routes of drug administration.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
Selected bioavailability and pharmacokinetic calculations Dr. Osama A. A. Ahmed.
Bioavailability and Bioequivalence
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Pharmacokinetics Calculations
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.
Gokaraju Rangaraju College of Pharmacy
DRUG BIOAVAILABILITY Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D
Week 6- Bioavailability and Bioequivalence
University of Jordan-Faculty of Pharmacy
ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,
Therapeutic Aerosols Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.
Bioavailability  The in- vitro methods of evaluating dosage forms provide only indirect evidence of the therapeutic utility of the drug in a given dosage.
SYSTEMIC ABSORPTION AS THE MOST ACCURATE AND SENSITIVE METHOD OF DETERMINING BIOEQUIVALENCE OF GENERIC TOPICAL PRODUCTS Chris Hendy Ph.D. Novum Pharmaceutical.
Bioavailability Dr Mohammad Issa.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
Center for Professional Advancement Generic Drug Approvals Course Bioequivalence & Bioavailability Michael A. Swit, Esq. Vice President.
Core Concepts in Pharmacology Chapter 5 Pharmacokinetics.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
Bioequivalence Dr Mohammad Issa Saleh.
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
PHYSICOCHEMICAL PRINCIPLES Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk,
Grade Statistics without Bonus with Bonus Average = 86 Median = 87 Average = 88 Median = 89 Undergraduates Average=88 MS Average=92.
PHARMACEUTICS- IV (PHT 414 ) Dr. Mohammad Khalid Anwer SALMAN BIN ABDUL AZIZ UNIVERSITY COLLEGE OF PHARMACY L111/16/2016.
INTRODUCTION CLINICAL PHARMACOKINETICS
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Introduction What is a Biowaiver?
Malaysia, EVALUTION OF DOSSIERS IN WHO- PREQUALIFICATION PROJECT MULTISOURCE TB-DRUGS Evaluation of bioavailability/bioequivalence data Based,
Bioavailability and Bioequivalence L 10,11.  Bioavailability is a measurement of the rate and extent (amount) to which the active ingredient or active.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Modified release products. Considerations in the evaluation of modified release products Requirements for preparing extended release products. The bioavailability.
Design of Sustained Release Dosage Forms
Storage of Pharmaceutical Products Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Equivalence pharmaceutical equivalents---drugs must have same active ingredients, in same strength, in same dosage form, same RofA. Inactive ingredients.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
PHT 415 BASIC PHARMACOKINETICS
Clearance and Renal Excretion Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk,
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy University of Andalas.
415 PHT Plasma Level – Time Curve
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Definitions and Concepts
BIOAVAILABILITY AND BIOEQUIVALENCE TESTING Department of Pharmaceutics.
Introduction to Biopharmaceutics and Pharmacokinetics
Drug Response Relationships
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Introduction What is a Biowaiver?
Prof. Dr. Basavaraj K. Nanjwade
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
BTP 3822 BIOPHARMACEUTICS Quiz I
Quantitative Pharmacokinetics
Clinical Pharmacokinetics
Clinical Pharmacokinetics
BIOPHARMACEUTICS All pharmaceuticals, from the generic analgesic tablet in the community pharmacy to the state-of-the-art immunotherapy in specialized.
Selected Bioavailability and Pharmacokinetic Calculations
1 Concentration-time curve
Basic Biopharmaceutics
Pharmacologic Principles (Lilley, p. 16)
Therapeutic Drug Monitoring chapter 1 part 1
Hawler Medical University
Presentation transcript:

Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya /03/151 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

CONTENTS 1.Concept and terminology. 2.Methods of assessing bioavailability. 3.Evaluation and design of a single dose bioequivalency study. 4.Determination of bioavailability and bioequivalency in multiple dose regimen. 5.References. 2014/03/152 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

What is Bioavailability Bioavailability, Indicates measurement of the rate and extent (amount) of therapeutically active drug that reaches the systemic circulation and is available at the site of action. 2014/03/153 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Concept of Bioavailability Rate and extent at which therapeutically active drug reaches systemic circulation. The fraction of administered dose that reaches the systemic circulation in contrast to that stated on label. Rate & extent of absorption of unchanged drug from its dosage form. A measure relative to some standard of rate & amount of drug, which reaches the systemic circulation unchanged following the administration of dosage form. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 4

Why bioavailability studies FDA requires that the drug product is safe and effective. Measure of bioavailability: AUC/dose. Absolute availability: Absolute availability for drugs with approved NDA, bioavailability studies are required for new drug formulations-bioequivalence to the reference formulation. Relative availability: Relative availability for drugs without full NDA, bioequivalence to the reference drug in the standard formulation. For determining safety and efficacy of drug product. 2014/03/155 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Types of Bioavailability  Absolute Bioavailability :- If the systemic availability of a drug administered orally is determined by doing its comparison with I.V. administration, it is known as absolute bioavailability. 2014/03/156 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Types of Bioavailability  Relative Bioavailability :- If the systemic availability of a drug administered orally is determined by doing its comparison with that of an oral standard of the same drug, it is known as a relative bioavailability. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 7

Types of Bioavailability  Range of Bioavailability – 0 to 1.  It is usually expressed as percentages (%).  An absolute bioavailability of 1 (or 100%) indicates complete absorption.  Relative bioavailability of 1 (or 100%) implies that the bioavailability of drug from both the dosage forms is the same but does not indicate the completeness of the systemic drug absorption. 2014/03/158 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

 Bioavailability of drug from dosage form depends upon following.  Route of administration  Patient related factors  Physicochemical properties of the drug  Characteristics of the dosage form 2014/03/159 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. Types of Bioavailability

Bioavailability The influence of route of administration on drug’s bioavailability is generally in the following order Parenteral > Oral > Rectal > Topical Most drugs are administered orally, for reason of stability and convenience. The dose available to patient – Bioavailable dose. 2014/03/1510 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Plasma concentration Time (hours) i.v. route oral route /03/1511 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. Bioavailability

Methods of assessing bioavailability Pharmacokinetic methods ( indirect ) 1. Blood analysis 2. Urinary excretion data Pharmacodynamic methods ( direct ) 1. Acute pharmacological response 2. Therapeutic response 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 12

Pharmacokinetic methods ( indirect ) 1. Blood analysis Plasma level time studies or The plasma concentration – time curve or blood level curve. A direct relationship exists concentration of drug at the site of action & concentration of drug in the plasma. Serial blood samples are taken after drug administration & analyzed for drug concentration. A typical blood level curve obtained after oral administration of drug. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 13

Pharmacokinetic methods ( indirect ) 2. Urinary excretion data The method of determination bioavailability provided that the active ingredient is excreted unchanged in the significant quantity of urine. The cumulative amount of active drug excreted in urine is directly proportional to extent of systemic drug absorption. The rate of drug excretion is directly proportional to rate of systemic drug absorption. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 14

Pharmacodynamic methods ( direct ) 1. Acute pharmacological response Bioavailability can be determined from the acute pharmacologic effect – time curve as well as from dose response graph. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 15

Pharmacodynamic methods ( direct ) 2. Therapeutic response This method is based on the observing the clinical response to a drug formulation given to a patients suffering from disease for which it is intended to be used. Eg. Anti inflammatory drugs, the reduction in the inflammation is determined. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 16

Pharmacokinetic and Pharmacodynamic Parameters 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 17

Parameters determined Pharmacokinetic parameters Peak Plasma Concentration (C max ) Time of Peak concentration (t max ). Area Under Curve (AUC) Pharmacodynamics parameters Minimum Effective Concentration (MEC) / Minimum Inhibitory Concentration (MIC). Maximum Safe Concentration (MSC) / Maximum Safe Dose (MSD). Duration of action Onset of action. Intensity of action. 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 18

AUC or Extent of absorption can be measured by 3 methods 1.Planimeter Instrument for mechanically measuring the area 2. Cut & weigh method AUC is cut & weighed on analytical balance. The weight obtained is converted to proper unit by dividing it by the wt of a unit area of same paper. 3. Trapezoidal method 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 19

AUC or Extent of absorption can be measured by 3 methods 3. Trapezoidal method AUC = ½ ( C 1 + C 2 ) (t 2 – t 1 ) + ½ (C 2 + C 3 ) (t 3 – t 2 ) +……. ½ (C n-1 + C n ) (t n – t n-1 ) C = Concentration t = time subscript= sample number AUC = Area Under Curve 2014/03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 20

AUC-Area under curve C max - Maximum concentration T max -Time to maximum concentration 2014/03/1521 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. Methods of assessing bioavailability

Bioequivalence -Bioequivalence means pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of the therapeutic moiety under similar experimental conditions. -Bioequivalence studies are usually performed to compare the rate and/or extent of absorption of a new drug product or a generic equivalent with that of a recognized standard. 2014/03/1522 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Dosage forms that are to be evaluated only for bioequivalence purpose. Dosage forms meant for a single dose administration for a therapeutic benefit such as analgesic for relief of headache. Evaluation and design of a single dose bioequivalency study 2014/03/1523 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Evaluation and design of a single dose bioequivalency study 2014/03/1524 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Determination of bioavailability and bioequivalency in multiple dose regimen Dosage forms designed to achieve special release profiles. e.g. time-release products, enteric-coated preparations. Drugs undergoing first pass metabolism. Special dosage regimens such as loading dose. 2014/03/1525 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Dosage forms designed to achieve special release profiles. e.g. time-release products, enteric-coated preparations. Drugs undergoing first pass metabolism. Special dosage regimens such as loading dose. Determination of bioavailability and bioequivalency in multiple dose regimen 2014/03/1526 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

Bioavailability and Bioequivalence Two dosage forms are bioequivalent: not bioequivalent: 2014/03/1527 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

References “Biopharmaceutics & Pharmacokinetics”, D. M. Brahmankar & Sunil B. Jaiswal, Vallabh Prakashan. “Text book of Biopharmaceutics & pharmacokinetics”, Dr. Shobharani R. Hiramath. “Applied Biopharmaceutics & pharmacokinetics”, Leon Shargel & Andrew B.C /03/1528 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya.

THANK YOU /03/15 Faculty of Pharmacy, Omer Al-Mukhtar University, Tobruk, Libya. 29